Showing results (2301-2310 of 2,601) with videos related to
Sort By:
Pageof 261
Oncogene|January 16, 2013
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagusM M Streppel, S Lata, M DelaBastide, et al.Genome Research|October 8, 2017
Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathwaysSanchari Bhattacharyya, Kith Pradhan, Nathaniel Campbell, et al.Scientific Reports|October 21, 2016
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinomaPeter Bailey, David K Chang, Marie-Andrée Forget, et al.Diabetes & Metabolic Syndrome|November 14, 2022
Cardiorenal disease management in type 2 diabetes: An expert consensusViswanathan Mohan, Awadhesh Kumar Singh, Abdul Hamid Zargar, et al.Cancers|June 28, 2023
Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and PancreatoduodenectomyTom Z Liang, Matthew H G Katz, Laura R Prakash, et al.Cancer Cell|July 5, 2003
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesisYoshiharu Miyamoto, Anirban Maitra, Bidyut Ghosh, et al.Journal of Medicinal Chemistry|October 15, 2019
Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in VivoMatthias Scheiner, Dominik Dolles, Sandra Gunesch, et al.Histopathology|May 7, 2015
The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyLaurice K Fischer, Matthew H Katz, Sun M Lee, et al.Molecular Cell|June 2, 2007
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosisTsung-Cheng Chang, Erik A Wentzel, Oliver A Kent, et al.Journal for Immunotherapy of Cancer|March 2, 2020
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancerMichael Overman, Milind Javle, Richard E Davis, et al.Pageof 261